Indications and uses
Technetium Tc 99m DMSA by intravenous administration is indicated as a static kidney imaging agent.
Technetium Tc 99m DMSA by intravenous administration is indicated as a static kidney imaging agent.
Preparation of Technetium Tc 99m DMSA is done by the following aseptic procedure: Waterproof gloves should be worn during the preparation Snap off the plastic lid and place room temperature reaction vial in an appropriate lead shield. Swab the rubber closure of the vial with a germicide Inject as close to 1 cc as possible of sterile additive free sodium pertechnetate Tc 99m injection containing up to 1480 MBq (40 ...
Dear Medical Professional,
Per your order, we have compounded DMSA as a sterile freeze-dried mixture. The characteristics of this preparation are:
AnazaoHealth supplies DMSA as a compounded kit for preparing Tc 99m DMSA. Each Reaction vial contains 1.1 mg meso-2, 3-dimercaptosuccinic acid, 0.2 mg tin as stannous chloride, and 0.7 mg ascorbic acid. The vial is back filled with inert gas and may contain a partial vacuum.
Each Acetate buffer vial contains 1.2 ml Sodium Acetate .25 N. pH 5.2 to 5.6.
LDO normal saline included for dilution of prepared kit, if required
Technetium Tc 99m DMSA, when administered intravenously apparently binds to plasma proteins in the blood and collects in the renal cortex.
Technetium Tc 99m DMSA by intravenous administration is indicated as a static kidney imaging agent.
There are no known contraindications.
Preparation of Technetium Tc 99m DMSA is done by the following aseptic procedure:
Tagging Tips
Store the kit at 2°-8°C (36°-46°F) and protect from light
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| c5cd4727-ac49-4409-82b1-5bd8006c3ec7 | Product name | 1 | 20171122 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 51808-211-01 | 2019-11-27 | C162847 | 48780-1 | 9855d018-deec-cd31-e053-dbdaa90ab51a | DMSA (Dimercaptosuccinic acid) |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 51808-211-01 | Dimercaptosuccinic AcidDMSA | 1 in 1 KIT | INJECTION, POWDER, LYOPHILIZED, | 1 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 51808-211 | DIMERCAPTOSUCCINIC ACID DMSA (DIMERCAPTOSUCCINIC ACID) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ANAZAOHEALTH CORPORATION] | 1 | Legacy NDC, 1 package rows | 20121203_5b11e596-3044-429b-9e48-33ba00946151.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| 2,3-DIMERCAPTOSUCCINIC ACID | ACTIVE INGREDIENT | 4S9JU7XF01 | 1 | |
| 2,3-DIMERCAPTOSUCCINIC ACID | ACTIVE MOIETY | 4S9JU7XF01 | 1 | |
| ASCORBIC ACID | INACTIVE INGREDIENT | PQ6CK8PD0R | 1 | |
| STANNOUS CHLORIDE | INACTIVE INGREDIENT | 1BQV3749L5 | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 51808-211 | 51808-211-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| 2,3-DIMERCAPTOSUCCINIC ACID | 4S9JU7XF01 | ACTIB |
| STANNOUS CHLORIDE | 1BQV3749L5 | IACT |
| ASCORBIC ACID | PQ6CK8PD0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| STANNOUS CHLORIDE | STANNOUS CHLORIDE | 1BQV3749L5 | INJECTION, POWDER, FOR SOLUTION / INTRADERMAL | 0.08 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | GEL / TOPICAL | 7 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | AEROSOL, SPRAY / RESPIRATORY (INHALATION) | 0.11 %w/w | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | TABLET / ORAL | 80 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 2 mg | ||
| STANNOUS CHLORIDE | STANNOUS CHLORIDE | 1BQV3749L5 | INJECTION / INTRAVENOUS | 3.4 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | INJECTION / INTRACAVITARY | 5 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | SOLUTION / ORAL | 600 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | TABLET, FILM COATED / ORAL | 20 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | CONCENTRATE / ORAL | 6 mg/1ml | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | POWDER, FOR SOLUTION / ORAL | 560 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | AEROSOL, METERED / RESPIRATORY (INHALATION) | 0.1 %w/w | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | SYRUP / ORAL | 200 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | INJECTION, SOLUTION / INFILTRATION | 0.2 %w/v | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1440 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | SUSPENSION / ORAL | 520 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | SOLUTION / TOPICAL | 0.04 %w/w | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | CAPSULE, EXTENDED RELEASE / ORAL | 17 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | TABLET, ORALLY DISINTEGRATING / ORAL | 2.35 mg | ||
| STANNOUS CHLORIDE | STANNOUS CHLORIDE | 1BQV3749L5 | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 0.25 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | SOLUTION / RESPIRATORY (INHALATION) | 0.04 %w/w | ||
| STANNOUS CHLORIDE | STANNOUS CHLORIDE | 1BQV3749L5 | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.08 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | SUPPOSITORY / RECTAL | 3 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | CAPSULE / ORAL | 7 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | INJECTION, SOLUTION / INTRAVENOUS | 4 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | INJECTION / INTRAVENOUS | 1440 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | CAPSULE, DELAYED RELEASE / ORAL | 12 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | SUSPENSION, EXTENDED RELEASE / ORAL | 6 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | INJECTION / INTRAMUSCULAR | 192 mg | ||
| STANNOUS CHLORIDE | STANNOUS CHLORIDE | 1BQV3749L5 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 0.42 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ec657ecb-6327-464c-8aab-6d61a0546b83 | 5b11e596-3044-429b-9e48-33ba00946151 | 2012-07-01 | ec657ecb-6327-464c-8aab-6d61a0546b83 5b11e596-3044-429b-9e48-33ba00946151 |
Adverse event summaries are temporarily unavailable. Other product information remains available.